Petrylak, D. P., Burotto, M., Reyes-Cosmelli, F., Cutuli, H. J., Huddart, R. A., Makharadze, T., Rey, J. P. M., Mazhar, D., Salas, I. M., Sankey, P., Seo, H. K., Xu, C., DeMars, L. R., Method, M., Loriot, Y. (2026). Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) in patients (pts) with previously treated locally advanced/metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4566